344285-84-3

Upstream product

• 69395-15-9 2-(2-chloro-4-nitro-phenyl)-ethanol 
• 121-86-8 2-chloro-4-nitrotoluene 

Downstream Products

• 344285-85-4 ethyl N-[3-chloro-4-(2-hydroxyethyl)phenyl]aminoacetate 
• 227467-82-5 ethyl N-[2,3-dichloro-4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxy-phenyl)-1-methylethyl]amino]ethyl]phenyl]aminoacetate 
• 227467-83-6 ethyl N-[2,5-dichloro-4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxy-phenyl)-1-methylethyl]amino]ethyl]phenyl]aminoacetate 
• 1028271-87-5 (3-Chloro-4-{2-[(1S,2R)-2-hydroxy-2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenylamino)-acetic acid ethyl ester 
• 227467-69-8 ethyl N-[4-(2-bromoethyl)-2,5-dichlorophenyl]aminoacetate 
• 227467-68-7 ethyl N-[4-(2-bromoethyl)-2,3-dichlorophenyl]aminoacetate 
• 227467-66-5 ethyl N-[4-(2-bromoethyl)-3-chlorophenyl]aminoacetate 

Relevant academic research and scientific papers

POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS

The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS

The invention features a hybridized polynucleotide construct containing a passenger strand, a guide strand loadable into a RISC complex, and (i) a 3'-terminal or an internucleotide non-bioreversible group in the guide strand; or (ii) a 5'-terminal, a 3'-terminal, or an internucleotide non-bioreversible group in the passenger strand, and a 5'-terminal, a 3'-terminal, or an internucleotide disulfide bioreversible group in the guide strand or the passenger strand. The invention also features methods of delivering a polynucleotide to a cell using the hybridized polynucleotide construct. The invention further features methods of reducing the expression of a polypeptide in a cell using the hybridized polynucleotide construct.

Discovery of novel N-phenylglycine derivatives as potent and selective β3-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence

With a novel assay using isolated ferret detrusor to estimate β3-adrenoceptor agonistic activity, we found that a series of glycine derivatives of ritodrine, a β2-adrenoceptor agonist, are potent β3-adrenoceptor agonists,